Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A real-life worldwide observational study (EDGE)

Vildagliptin more effectively achieves a composite endpoint of HbA1c

(2013) Giovanni Bader et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Quality of Diabetes Care in Italy: Information From a Large Population-Based Multiregional Observatory (ARNO Diabetes)

(2012) G. Bruno et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes

(2011) R. R. Wing et al.   DIABETES CARE

Pragmatic Trials — Guides to Better Patient Care?

(2011) James H. Ware et al.   NEW ENGLAND JOURNAL OF MEDICINE

The lack of knowledge about the voluntary reporting system of adverse drug reactions as a major cause of underreporting: direct survey among health professionals

(2011) Mariley Pérez García et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

(2010) M. Ligueros-Saylan et al.   DIABETES OBESITY & METABOLISM

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

(2010) A. Schweizer et al.   DIABETES OBESITY & METABOLISM

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

(2010) C. Filozof et al.   DIABETIC MEDICINE

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin

(2009) G. Bolli et al.   DIABETES OBESITY & METABOLISM

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

(2009) E. Ferrannini et al.   DIABETES OBESITY & METABOLISM

Explanatory and Pragmatic Attitudes in Therapeutical Trials

(2009) Daniel Schwartz et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Making trials matter: pragmatic and explanatory trials and the problem of applicability

(2009) Shaun Treweek et al.   Trials

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE